European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

ConditionsLung Diseases, Interstitial Pulmonary Alveolar Proteinosis Pulmonary Eosinophilia Pulmonary Fibrosis Respiratory Distress Syndrome, Newborn Child

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorMatthias Griese

About this trial

Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes

Eligibility criteria

Qualifiers

all children with suspected or

verified diagnosis of ILD or

masquerading as ILD and

those with rare localized parenchymal lung diseases

Disqualifiers

other indication as inclusion criteria

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

Germany

Medizinische Hochschule Hannover30625, HanoverLower Saxony, Germany

Turkey (Türkiye)

Hacettepe University, Medical Faculty06100, AnkaraSihhiye, Turkey (Türkiye)

United Kingdom

University of EdinburghEH4 2XU, Edinburgh United Kingdom

Sponsors and collaborators

Matthias Griese

Lead sponsor

Ludwig-Maximilians - University of Munich

Sponsor institution

Source ClinicalTrials.gov